BayWa's Overhaul Stumbles as Auditor Exit Compounds Financial Strain

BayWa faces legal scrutiny and a delayed audit after PwC dismissal. Asset sales provide cash, but creditor talks and a €4B restructuring target pressure the stock.

The German agricultural trading group BayWa finds itself navigating a perfect storm of financial restructuring and legal scrutiny. While a recent asset sale provides a crucial cash injection, the simultaneous dismissal of its long-term auditor PwC and a delayed financial report have plunged the company into deeper uncertainty, keeping its share price under severe pressure.

Investors are grappling with a significant information void. BayWa has severed ties with auditor PwC following a controversial clean audit opinion for the crisis-ridden 2023 financial year. German financial watchdog BaFin has since reprimanded the company for failing to disclose existential risks, including crucial details on a billion-euro loan and refinancing risks for a €500 million bond. This regulatory action forms the basis for potential shareholder lawsuits. Prosecutors in Munich I are also investigating former CEO Marcus Pöllinger on suspicion of breach of trust. Even BayWa's current management is now examining potential claims against the auditors.

This auditor upheaval creates a major administrative bottleneck. PwC will audit the company for the final time for the 2025 fiscal year, but this report is now delayed until the fourth quarter of 2026. The holdup is due to a mandatory revaluation of the renewable energy subsidiary BayWa r.e., further complicating the group's transformation.

Financially, the path to stability remains steep. The company's overarching restructuring target is €4 billion. To date, only €1.3 billion of this goal has been secured. A planned partial sale of the energy unit collapsed after the US cut subsidies for renewable energy projects, causing the targeted sale price to vanish. In response, management withdrew its financial forecast for 2026 and announced plans to cut 1,300 jobs.

Amid these setbacks, the recent sale of the Dutch subsidiary Cefetra offers a glimmer of operational relief. The deal, along with the repayment of shareholder loans, is expected to bring a cash inflow of approximately €107 million by the end of April. This includes €45 million from the Cefetra sale directly and a further €62 million from loan repayments. The transaction also removes over €600 million in bank liabilities from BayWa's balance sheet.

However, the company's fate is ultimately in the hands of its core creditors, DZ Bank and HVB. BayWa is currently negotiating an extension of its standstill agreement with these banks until autumn 2026. Their consent is critical; without it, the entire restructuring plan faces immediate refinancing pressure. The upcoming €45 million payment from the Cefetra deal at the end of April serves as an initial test of this fragile creditor relationship.

Market sentiment reflects the profound unease surrounding BayWa's recovery timeline. The stock, currently trading at €13.60, has lost 18.81% since the start of the year. It continues to trade roughly 20% below its 200-day moving average, signaling persistent investor doubt. A decisive turning point is not expected before late 2026, when a final bank agreement and the audited 2025 financial statements are due. Until then, the market is left to operate without reliable fundamental data.